Versant Capital Management, Inc Supernus Pharmaceuticals, Inc. Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 999 shares of SUPN stock, worth $33,556. This represents 0.0% of its overall portfolio holdings.
Number of Shares
999
Previous 1,125
11.2%
Holding current value
$33,556
Previous $36,000
13.89%
% of portfolio
0.0%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding SUPN
# of Institutions
302Shares Held
60.7MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$349 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$207 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$175 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$97.5 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$90.7 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.8B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...